Eli Lilly Revenue Surges 55.5% on Mounjaro Sales, But Stock Lags Amid Pricing Pressures
Summary
Eli Lilly reported strong Q1 results with 55.5% revenue growth to $19.80 billion, driven by Mounjaro's $8.66 billion in sales. The company raised full-year guidance to $82-$85 billion. Despite these positive results, the stock has only risen 2.57% year-to-date to $1,098.57 and fell 5.37% after hitting $1,160.95 on June 11. Challenges include a 13% decline in realized prices due to Mounjaro's addition to China's NRDL formulary, compressed international margins, and $584 million in IPR&D charges. Analyst consensus targets $1,215.79, with internal projections reaching $1,279.62.
Source
bskyEli Lilly Revenue Surges 55.5% on Mounjaro Sales, But Stock Lags Amid Pricing Pressuresbriefly.coKey quotes
· 4 pulledRevenue increased 55.5% year over year to $19.80 billion, with Mounjaro generating $8.66 billion.
Full-year guidance was raised to $82 to $85 billion.
Realized prices declined 13% in Q1 due to Mounjaro's addition to China's NRDL formulary, compressing international margins.
The consensus target is $1,215.79, while an internal base case targets $1,279.62 with 90% confidence.
You might also wanna read
Reliance Industries Media Arm Reports $3.7 Billion Revenue in FY26, Driven by IPL and Dhurandhar Franchise
Reliance Industries' media and entertainment division generated $3.7 billion (INR 34,917 crore) in revenue for FY26, as disclosed by Chairma
Variety·5d ago
OpenAI Partnership Announcements Drive Stock Gains for Partner Companies
OpenAI's partnership announcements with public companies consistently drive stock price increases, as demonstrated by AMD's stock rising 29%
bloomberg.com·8mo ago
SpaceX, Anthropic, and OpenAI prepare for record-breaking IPOs totaling up to $4 trillion
Three major companies—SpaceX, Anthropic, and OpenAI—are preparing for massive IPOs that could collectively add up to $4 trillion to the stoc
economist.com·23d agoComments
Sign in to join the conversation.
No comments yet. Be the first.